Tags

Type your tag names separated by a space and hit enter

C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy.
Diabetes Care 2007; 30(1):71-6DC

Abstract

OBJECTIVE

C-peptide replacement in animals results in amelioration of diabetes-induced functional and structural abnormalities in peripheral nerves. The present study was undertaken to examine whether C-peptide administration to patients with type 1 diabetes and peripheral neuropathy improves sensory nerve function.

RESEARCH DESIGN AND METHODS

This was an exploratory, double-blinded, randomized, and placebo-controlled study with three study groups that was carried out at five centers in Sweden. C-peptide was given as a replacement dose (1.5 mg/day, divided into four subcutaneous doses) or a dose three times higher (4.5 mg/day) during 6 months. Neurological examination and neurophysiological measurements were performed before and after 6 months of treatment with C-peptide or placebo.

RESULTS

The age of the 139 patients who completed the protocol was 44.2 +/- 0.6 (mean +/- SE) years and their duration of diabetes was 30.6 +/- 0.8 years. Clinical neurological impairment (NIA) (score >7 points) of the lower extremities was present in 86% of the patients at baseline. Sensory nerve conduction velocity (SCV) was 2.6 +/- 0.08 SD below body height-corrected normal values at baseline and improved similarly within the two C-peptide groups (P < 0.007). The number of patients responding with a SCV peak potential improvement >1.0 m/s was greater in C-peptide-treated patients than in those receiving placebo (P < 0.03). In the least severely affected patients (SCV < 2.5 SD below normal at baseline, n = 70) SCV improved by 1.0 m/s (P < 0.014 vs. placebo). NIA score and vibration perception both improved within the C-peptide-treated groups (P < 0.011 and P < 0.002). A1C levels (7.6 +/- 0.1% at baseline) decreased slightly but similarly in C-peptide-and placebo-treated patients during the study.

CONCLUSIONS

C-peptide treatment for 6 months improves sensory nerve function in early-stage type 1 diabetic neuropathy.

Authors+Show Affiliations

Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. karin.ekberg@creativepeptides.seNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

17192336

Citation

Ekberg, Karin, et al. "C-Peptide Replacement Therapy and Sensory Nerve Function in Type 1 Diabetic Neuropathy." Diabetes Care, vol. 30, no. 1, 2007, pp. 71-6.
Ekberg K, Brismar T, Johansson BL, et al. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy. Diabetes Care. 2007;30(1):71-6.
Ekberg, K., Brismar, T., Johansson, B. L., Lindström, P., Juntti-Berggren, L., Norrby, A., ... Wahren, J. (2007). C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy. Diabetes Care, 30(1), pp. 71-6.
Ekberg K, et al. C-Peptide Replacement Therapy and Sensory Nerve Function in Type 1 Diabetic Neuropathy. Diabetes Care. 2007;30(1):71-6. PubMed PMID: 17192336.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy. AU - Ekberg,Karin, AU - Brismar,Tom, AU - Johansson,Bo-Lennart, AU - Lindström,Per, AU - Juntti-Berggren,Lisa, AU - Norrby,Anders, AU - Berne,Christian, AU - Arnqvist,Hans J, AU - Bolinder,Jan, AU - Wahren,John, PY - 2006/12/29/pubmed PY - 2007/3/7/medline PY - 2006/12/29/entrez SP - 71 EP - 6 JF - Diabetes care JO - Diabetes Care VL - 30 IS - 1 N2 - OBJECTIVE: C-peptide replacement in animals results in amelioration of diabetes-induced functional and structural abnormalities in peripheral nerves. The present study was undertaken to examine whether C-peptide administration to patients with type 1 diabetes and peripheral neuropathy improves sensory nerve function. RESEARCH DESIGN AND METHODS: This was an exploratory, double-blinded, randomized, and placebo-controlled study with three study groups that was carried out at five centers in Sweden. C-peptide was given as a replacement dose (1.5 mg/day, divided into four subcutaneous doses) or a dose three times higher (4.5 mg/day) during 6 months. Neurological examination and neurophysiological measurements were performed before and after 6 months of treatment with C-peptide or placebo. RESULTS: The age of the 139 patients who completed the protocol was 44.2 +/- 0.6 (mean +/- SE) years and their duration of diabetes was 30.6 +/- 0.8 years. Clinical neurological impairment (NIA) (score >7 points) of the lower extremities was present in 86% of the patients at baseline. Sensory nerve conduction velocity (SCV) was 2.6 +/- 0.08 SD below body height-corrected normal values at baseline and improved similarly within the two C-peptide groups (P < 0.007). The number of patients responding with a SCV peak potential improvement >1.0 m/s was greater in C-peptide-treated patients than in those receiving placebo (P < 0.03). In the least severely affected patients (SCV < 2.5 SD below normal at baseline, n = 70) SCV improved by 1.0 m/s (P < 0.014 vs. placebo). NIA score and vibration perception both improved within the C-peptide-treated groups (P < 0.011 and P < 0.002). A1C levels (7.6 +/- 0.1% at baseline) decreased slightly but similarly in C-peptide-and placebo-treated patients during the study. CONCLUSIONS: C-peptide treatment for 6 months improves sensory nerve function in early-stage type 1 diabetic neuropathy. SN - 0149-5992 UR - https://www.unboundmedicine.com/medline/citation/17192336/C_Peptide_replacement_therapy_and_sensory_nerve_function_in_type_1_diabetic_neuropathy_ L2 - http://care.diabetesjournals.org/cgi/pmidlookup?view=long&amp;pmid=17192336 DB - PRIME DP - Unbound Medicine ER -